Category: Uncategorized

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

admin | March 17, 2026

Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment…

READ MORE

AN2 Therapeutics Announces $40 Million Private Placement Financing

admin | March 9, 2026

MENLO PARK, Calif. –(BUSINESS WIRE)–Mar. 9, 2026– AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for

READ MORE